Japan 2014: Regulatory Moves, Suspect Practices, And Acquisitions
This article was originally published in PharmAsia News
If you missed any of the major news and analysis from Japan in 2014, here's your opportunity to check out PharmAsia News' view of the most important stories of the year. If there was any one overriding trend to pick out, it was the push towards more efficient regulation and the shaping of policy to support medical research in a rapidly aging society.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.